Composition, form of production and packaging
Solution for injections is transparent, colorless.
1 ml of 1 amp.
meldonia dihydrate * 100 mg 500 mg,
which corresponds to the content of meldonia 80.2 mg 401 mg
Auxiliary substances: water d / and.
* trimethylhydrazinium propionate dihydrate (in terms of dihydrate without adsorbed moisture).
5 ml - ampoules (5) - packings of cellular contour (1) - packs cardboard.
5 ml - ampoules (5) - packings of cellular contour (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
A drug that improves the metabolism and energy supply of tissues, a synthetic analogue of gamma-butyrobetaine. It suppresses gamma-butyrobetaine hydroxynase.Reduces the synthesis of carnitine and the transport of long chain fatty acids through cell membranes, prevents the accumulation of activated forms of unoxidized fatty acids - the derivatives of acylcarnitine and acylcoenzyme A in cells. Under conditions of ischemia, it restores the equilibrium of the processes of oxygen delivery and its consumption in cells, prevents the violation of ATP transport. Simultaneously, it activates glycolysis, which proceeds without additional consumption of oxygen. As a result of a decrease in the concentration of carnitine, gamma-butyrobetaine, which has vasodilating properties, is synthesized intensively.
The mechanism of action determines the variety of pharmacological effects of the drug: increasing efficiency, reducing the symptoms of mental and physical overstrain, the activation of tissue and humoral immunity, cardioprotective action.
In the case of acute ischemic damage, the myocardium slows the formation of the necrotic zone, shortens the rehabilitation period.
With heart failure increases myocardial contractility, increases exercise tolerance, reduces the incidence of angina attacks.
In acute and chronic ischemic disorders of cerebral circulation improves blood circulation in the ischemic focus, promotes redistribution of blood in favor of the ischemic site.
Effective in the case of vascular and dystrophic pathology of the fundus.
Characteristic is also a tonic effect on the central nervous system, the elimination of functional disorders of somatic and autonomic nervous systems in patients with chronic alcoholism with withdrawal syndrome.
Data on the pharmacokinetics of the Cardionate preparation are not available.
- reduced working capacity;
- increased physical activity;
- Postoperative period to accelerate rehabilitation;
- in the combined therapy of IHD, chronic heart failure, cardialgia against the background of dyshormonal myocardial dystrophy;
- complex therapy of withdrawal alcohol syndrome;
- Acute and chronic forms of cerebral circulation disorders;
- Acute circulatory disturbance in the retina, hemophthalmia and hemorrhage into the retina of various etiologies;
- thrombosis of the central vein of the retina and its branches;
- Retinopathy of various etiologies (including diabetic and hypertensive) - only for parabulbar injection.
Elevated mental and physical loads: iv in 1 g (10 ml) 1 time / day. The course of treatment is 10-14 days. If necessary, repeat the course after 2-3 weeks.
In cardiovascular diseases (as part of complex therapy): iv 0.5-1 g (5-10 ml); course of treatment - 10-14 days.
Violation of cerebral circulation: acute phase - IV 500 mg (5 ml) 1 time / day for 7-10 days, then switch to oral administration.
Chronic insufficiency of cerebral circulation: in / m 500 mg (5 ml) 1 time / day. The course of treatment - 10-14 days, then go to the reception inside.
Chronic alcoholism: in / in - 500 mg (5 ml) 2 times / day. The course of treatment is 7-10 days.
Vascular pathology of the fundus and dystrophy of the retina: retrobulbarno and subconjunctivally injected 50 mg (0.5 ml solution for injection) for 10 days.
From the cardiovascular system: rarely - tachycardia, changes in blood pressure.
Other: rarely - allergic reactions, dyspepsia, agitation.
- Increase in intracranial pressure (with violation of venous outflow and intracranial tumors);
- lactation period;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The drug is contraindicated for use in pregnancy and lactation (breastfeeding).
Cardiotion is not a first-line drug in acute coronary syndrome and its use is not an urgent need.
Impact on the ability to drive vehicles and manage mechanisms
There is no data on the adverse effects of Cardion on the rate of psychomotor reactions.
Data on the overdose of the drug Cardionate are not provided.
Strengthens the coronary arthritis and some antihypertensive medications, cardiac glycosides.
You can combine with antianginal drugs, anticoagulants, antiaggregants, antiarrhythmic drugs, diuretics, bronchodilators.
In view of the possible development of moderate tachycardia and arterial hypotension, caution should be exercised when combined with nitroglycerin, nifedipine, alpha-adrenoblockers, antihypertensive drugs and peripheral vasodilators.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
List B. The drug should be stored out of reach of children at a temperature of no higher than 25 В° C. Shelf life - 2 years.